Biopharma needs a biggie to avoid a down deal year
M&A picked up in the third quarter but overall 2021 has been quiet on the takeover front.
Biopharma’s stock market winners and losers so far this year
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
Biotech listings show signs of a slowdown
2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.
Global pharma stocks struggle in the third quarter
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
Covid-19 research efforts slow
A few developers are still finding reasons to research novel pandemic treatments, though much of the ongoing work is focused on proven approaches.
The sellside’s most controversial products
Drugs prompting the most divergent opinions on outlook include Pfizer and Vir’s Covid-19 offerings and Biogen’s Aduhelm.
Trillium buyout keeps premiums keen
The average takeout premium for a research-stage biotech is tracking at 100% this year, the latest data show.
Cancer continues to dominate deal making
Since 2016 drug developers have spent $23.6bn in-licensing cancer projects, almost half of the sector’s up-front bill.
EQRX aims for biopharma Spac record
Spac redemptions are a growing concern, but the $1.8bn EQRX deal looks primed to succeed. Proving the business model will be the hard part.
